Pharmaceuticals US

US Liver Cirrhosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Liver Cirrhosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Cause, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.32 Bn Placeholder estimate
Estimate 2025 $4.44 Bn 36.6% of the global market
Projected 2034 $5.69 Bn 28.2% Adds $1.25 Bn over 9 forecast years
CAGR 2025–2034 2.8% Faster than 15% of 180 Pharmaceuticals markets here
Key players 5
  • US is 36.6% of the global market.
  • In North America, the largest is US (this report) at $4.44 Bn.
  • Fastest growing: Canada at 5.2% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.25 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Liver Cirrhosis Treatment Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.32 Bn — —
2025 (base) $4.44 Bn +$120.9 Mn —
2026 (forecast) $4.56 Bn +$124.3 Mn +2.8%
2027 (forecast) $4.69 Bn +$127.8 Mn +5.7%
2028 (forecast) $4.82 Bn +$131.3 Mn +8.6%
2029 (forecast) $4.96 Bn +$135.0 Mn +11.7%
2030 (forecast) $5.10 Bn +$138.8 Mn +14.8%
2031 (forecast) $5.24 Bn +$142.7 Mn +18%
2032 (forecast) $5.39 Bn +$146.7 Mn +21.3%
2033 (forecast) $5.54 Bn +$150.8 Mn +24.7%
2034 (forecast) $5.69 Bn +$155.0 Mn +28.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Liver Cirrhosis Treatment Market Analysis at a glance
Market size, 2025$4.44 Bn placeholder estimate
Forecast, 2034$5.69 Bn placeholder estimate
Growth (CAGR), 2025–20342.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, cause and end user (see all)
Key playersSalix (Bausch Health), Gilead Sciences, Inc., Madrigal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Novo Nordisk A/S (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials135 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Liver Cirrhosis Treatment Market Analysis Executive Summary

Liver cirrhosis treatments manage scarring of the liver and its complications such as fluid build-up and confusion.

Key segments of the liver Cirrhosis Treatment market include treatment (Medications, Liver Transplant and Nutrition Support) and cause (Alcohol-Related, MASH-Related and Viral Hepatitis).

Bar chart: US Liver Cirrhosis Treatment market size, 2024–2034, placeholder estimates. $4.32 Bn in 2024, $4.44 Bn in 2025 and $5.69 Bn in 2034, 2.8% CAGR.
US Liver Cirrhosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Liver Cirrhosis Treatment Market Dynamics

Market Growth Drivers

Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the liver Cirrhosis Treatment market.

Opportunity

Microbiome-based treatments, earlier testing and digital gut-health programmes give the liver Cirrhosis Treatment market room to grow.

Market Restraints

Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the liver Cirrhosis Treatment market.

Competitive Landscape for Liver Cirrhosis Treatment Market in US

The liver Cirrhosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Liver Cirrhosis Treatment Market in US

Liver Cirrhosis Treatment in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 135 studies on Liver Cirrhosis Treatment that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for liver Cirrhosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Liver Cirrhosis Treatment right now, from free public sources.

Latest research 4,837 papers since 2021 (worldwide)

  1. Pleural empyema and perisplenic abscess caused by Clostridioides difficile in a patient with liver cirrhosis and previous C. difficile colitis: a case report. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026
  2. Recent recommendations for the diagnosis and management of liver cirrhosis and its complications. Expert review of gastroenterology & hepatology, 2026
  3. [Alcoholic Myopathy]. Brain and nerve = Shinkei kenkyu no shinpo, 2026
  4. Total glucosides of paeony in cirrhosis: mechanisms of action via the gut-liver axis - a review. Frontiers in gastroenterology (Lausanne, Switzerland), 2026
  5. Hepatic Erbin loss promotes CCl(4)-induced liver fibrosis by potentiating the TGF-β/Smad signaling in hepatocytes. Toxicology letters, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Liver Cirrhosis Treatment in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Liver Cirrhosis Treatment market in the US?
Placeholder estimate: about $4.44 Bn in 2025, rising to about $5.69 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Liver Cirrhosis Treatment market in the US growing?
Placeholder estimate: about 2.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Liver Cirrhosis Treatment market report cover?
The report splits the market by treatment (Medications, Liver Transplant, Nutrition Support), cause (Alcohol-Related, MASH-Related, Viral Hepatitis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Liver Cirrhosis Treatment market?
Key players include Salix (Bausch Health), Gilead Sciences, Inc., Madrigal Pharmaceuticals, Mallinckrodt Pharmaceuticals and Novo Nordisk A/S.
What is driving the Liver Cirrhosis Treatment market?
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the liver Cirrhosis Treatment market.
Who regulates Liver Cirrhosis Treatment in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Liver Cirrhosis Treatment are running in the US?
135 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Liver Cirrhosis Treatment?
PubMed lists 4,837 papers on Liver Cirrhosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on liver health and alcohol

See the topic